EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multicenter, Phase Ib trial designed to evaluate the safety, tolerability, and preliminary efficacy of EMB-01 in combination with chemotherapy in patients with unresectable or metastatic colorectal cancer (CRC), and to determine the recommended Phase II combination dose (RP2CD). The study consists of a dose escalation phase followed by a dose expansion phase. Approximately 30 patients are planned to be enrolled in each combination treatment group across both phases, with a maximum total enrollment of approximately 120 patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzony zaawansowany lub przerzutowy rak jelita grubego, który nie może być operacyjnie usunięty
- •Dobry ogólny stan zdrowia (ECOG ≤ 1)
- •Zgoda na dostarczenie próbki nowotworu do badania
- •Prawidłowe funkcjonowanie narządów wewnętrznych
- •Przerwa co najmniej 4 tygodnie od poprzedniej terapii przeciwnowotworowej
✗ Disqualifies
- •Wcześniejsze leczenie niektórymi lekami (w zależności od grupy badawczej)
- •Stosowanie radioterapii w ostatnich 2 tygodniach (poza wyjątkami)
- •Stosowanie radioaktywnych leków w ostatnich 8 tygodniach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 74 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Beijing Cancer Hospital
Beijing, China
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Trial contact
Ying Wu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.